Search alternatives:
significant effects » significant effect (Expand Search), significantly affected (Expand Search)
effects decrease » effects decreased (Expand Search), effects regress (Expand Search)
linked decrease » marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
significant effects » significant effect (Expand Search), significantly affected (Expand Search)
effects decrease » effects decreased (Expand Search), effects regress (Expand Search)
linked decrease » marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
-
3041
-
3042
-
3043
-
3044
PRISMA flow chart of the screening process.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
3045
Forest plot of liver function tests.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
3046
Subgroup analysis of BUN based on pump type.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
3047
Subgroup analysis of ICU Stay based on pump type.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
3048
Subgroup analysis of eGFR based on pump type.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
3049
GRADE evidence profile.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
3050
Characteristics of included studies.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
3051
Sensitivity analysis for eGFR.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
3052
Sensitivity analysis for BUN.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
3053
Subgroup analysis of BUN based on surgery type.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
3054
Baseline Characteristics of Included Patients.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
3055
-
3056
Image 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.pdf
Published 2025“…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. The complex pathogenesis and therapeutic resistance characteristic of liver hepatocellular carcinoma (LIHC) present significant challenges in clinical practice. …”
-
3057
Table 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx
Published 2025“…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. The complex pathogenesis and therapeutic resistance characteristic of liver hepatocellular carcinoma (LIHC) present significant challenges in clinical practice. …”
-
3058
Table 2_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx
Published 2025“…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. The complex pathogenesis and therapeutic resistance characteristic of liver hepatocellular carcinoma (LIHC) present significant challenges in clinical practice. …”
-
3059
Image 2_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.pdf
Published 2025“…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. The complex pathogenesis and therapeutic resistance characteristic of liver hepatocellular carcinoma (LIHC) present significant challenges in clinical practice. …”
-
3060